These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 7821752)

  • 41. Unusual joining sites in the H and L chains of an anti-lysozyme antibody.
    Hartman AB; Mallett CP; Sheriff S; Smith-Gill SJ
    J Immunol; 1988 Aug; 141(3):932-6. PubMed ID: 3135317
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interaction between the antigen and antibody is controlled by the constant domains: normal mode dynamics of the HEL-HyHEL-10 complex.
    Adachi M; Kurihara Y; Nojima H; Takeda-Shitaka M; Kamiya K; Umeyama H
    Protein Sci; 2003 Oct; 12(10):2125-31. PubMed ID: 14500870
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Some correlations between specificity and sequence of the first complementarity-determining segments of human kappa light chains.
    Kabat EA; Wu TT; Bilofsky H
    Proc Natl Acad Sci U S A; 1976 Dec; 73(12):4471-3. PubMed ID: 826908
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modeling the binding sites of anti-hen egg white lysozyme antibodies HyHEL-8 and HyHEL-26: an insight into the molecular basis of antibody cross-reactivity and specificity.
    Mohan S; Sinha N; Smith-Gill SJ
    Biophys J; 2003 Nov; 85(5):3221-36. PubMed ID: 14581222
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The structural basis of antigen-antibody recognition.
    Mariuzza RA; Phillips SE; Poljak RJ
    Annu Rev Biophys Biophys Chem; 1987; 16():139-59. PubMed ID: 2439094
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Conserved aromatic residues as determinants in the folding and assembly of immunoglobulin variable domains.
    Campion SR
    Mol Immunol; 2016 Feb; 70():63-71. PubMed ID: 26742085
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Length distribution of CDRH3 in antibodies.
    Wu TT; Johnson G; Kabat EA
    Proteins; 1993 May; 16(1):1-7. PubMed ID: 8497480
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chromatin specificity of anti-double-stranded DNA antibodies and a role for Arg residues in the third complementarity-determining region of the heavy chain.
    Guth AM; Zhang X; Smith D; Detanico T; Wysocki LJ
    J Immunol; 2003 Dec; 171(11):6260-6. PubMed ID: 14634143
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Peptidomimics of antigen are present in variable region of heavy and light chains of anti-idiotypic antibody and function as surrogate antigen for perpetuation of immunological memory.
    Vani J; Justin J; Nagasuma RC; Nayak R; Shaila MS
    Mol Immunol; 2007 Jul; 44(13):3345-54. PubMed ID: 17408744
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recombinant shark natural antibodies to thyroglobulin.
    Schluter SF; Jensen I; Ramsland PA; Marchalonis JJ
    J Mol Recognit; 2005; 18(5):404-12. PubMed ID: 15954089
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structural basis of p21H-ras molecular switch inhibition by a neutralizing antibody.
    Gallagher WM; Grant GH
    J Mol Graph; 1996 Feb; 14(1):42-50, 28-9. PubMed ID: 8744572
    [TBL] [Abstract][Full Text] [Related]  

  • 52. VL-VH expression by monoclonal antibodies recognizing avian lysozyme.
    Smith-Gill SJ; Mainhart CR; Lavoie TB; Rudikoff S; Potter M
    J Immunol; 1984 Feb; 132(2):963-7. PubMed ID: 6418816
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Catalytic antibody model and mutagenesis implicate arginine in transition-state stabilization.
    Roberts VA; Stewart J; Benkovic SJ; Getzoff ED
    J Mol Biol; 1994 Jan; 235(3):1098-116. PubMed ID: 8289310
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Unusual distributions of amino acids in complementarity-determining (hypervariable) segments of heavy and light chains of immunoglobulins and their possible roles in specificity of antibody-combining sites.
    Kabat EA; Wu TT; Bilofsky H
    J Biol Chem; 1977 Oct; 252(19):6609-16. PubMed ID: 408353
    [No Abstract]   [Full Text] [Related]  

  • 55. Antibody diversity versus antibody complementarity.
    Kabat EA
    Pharmacol Rev; 1982 Mar; 34(1):23-38. PubMed ID: 6803258
    [No Abstract]   [Full Text] [Related]  

  • 56. Fine specificity and sequence of antibodies directed against the ectodomain of matrix protein 2 of influenza A virus.
    Zhang M; Zharikova D; Mozdzanowska K; Otvos L; Gerhard W
    Mol Immunol; 2006 Jul; 43(14):2195-206. PubMed ID: 16472860
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Origins of antibody complementarity and specificity--hypervariable regions and minigene hypothesis.
    Kabat EA
    J Immunol; 1980 Sep; 125(3):961-9. PubMed ID: 6774021
    [No Abstract]   [Full Text] [Related]  

  • 58. Crystal structure of the complex of the variable domain of antibody D1.3 and turkey egg white lysozyme: a novel conformational change in antibody CDR-L3 selects for antigen.
    Braden BC; Fields BA; Ysern X; Goldbaum FA; Dall'Acqua W; Schwarz FP; Poljak RJ; Mariuzza RA
    J Mol Biol; 1996 Apr; 257(5):889-94. PubMed ID: 8632472
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular dynamics simulation of a high-affinity antibody-protein complex: the binding site is a mosaic of locally flexible and preorganized rigid regions.
    Sinha N; Smith-Gill SJ
    Cell Biochem Biophys; 2005; 43(2):253-73. PubMed ID: 16049350
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Structural consequences of target epitope-directed functional alteration of an antibody. The case of anti-hen lysozyme antibody, HyHEL-10.
    Kumagai I; Nishimiya Y; Kondo H; Tsumoto K
    J Biol Chem; 2003 Jul; 278(27):24929-36. PubMed ID: 12709438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.